发明名称 |
Pharmaceutical combination for the treatment and/or chemosensibilization of refractory tumors to anticancer drugs |
摘要 |
This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemothearapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa and velcade (bortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics. |
申请公布号 |
US9226946(B2) |
申请公布日期 |
2016.01.05 |
申请号 |
US201414490856 |
申请日期 |
2014.09.19 |
申请人 |
BIOREC S.A.;CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA |
发明人 |
Perea Rodríguez Silvio Ernesto;Perera Negrín Yasser;Rodríguez Ulloa Arielis;Gil Valdés Jeovanis;Ramos Gómez Yassel;Castellanos Serra Lila Rosa;Betancourt Núñez Lázaro Hiram;Sánchez Puente Aniel;Fernández de Cossio Dorta Duque Jorge;Acevedo Castro Boris Ernesto;González López Luis Javier;Besada Pérez Vladimir;Alonso Daniel Fernando;Gomez Daniel Eduardo |
分类号 |
A61K38/04;C07K7/00;A61K38/08;A61K31/555;A61K33/24;A61K45/06;A61K31/337;A61K31/407;A61K31/475;A61K31/506;A61K31/513;A61K31/5377;A61K31/675;A61K31/69;A61K31/704 |
主分类号 |
A61K38/04 |
代理机构 |
Hoffman & Baron, LLP |
代理人 |
Hoffman & Baron, LLP |
主权项 |
1. A method to decrease the chemoresistance of a tumor to a cytostatic drug, said method comprising administering simultaneously, separately or sequentially to said tumor, the P15 peptide identified as SEQ ID NO: 1, and the cytostatic drug wherein said cytostatic drug is selected from the group consisting of: Cisplatin, Paclitaxel, 5-Fluorouracil, Vincristin, Vinblastin, Doxorubicin, Docetaxel, Cyclophosphamide, Mitomycin C, Imatinib, Bortezomib and Iressa. |
地址 |
Montevideo UY |